These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

741 related items for PubMed ID: 25218310

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL, Tyor WR.
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [Abstract] [Full Text] [Related]

  • 3. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C, Aloi JJ.
    Clin Ther; 2015 Apr 01; 37(4):691-715. PubMed ID: 25846320
    [Abstract] [Full Text] [Related]

  • 4. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Ingwersen J, Aktas O, Hartung HP.
    Neurotherapeutics; 2016 Jan 01; 13(1):47-57. PubMed ID: 26701666
    [Abstract] [Full Text] [Related]

  • 5. Teriflunomide for multiple sclerosis.
    He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.
    Cochrane Database Syst Rev; 2012 Dec 12; 12():CD009882. PubMed ID: 23235682
    [Abstract] [Full Text] [Related]

  • 6. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R, Harel A, Lublin F.
    Annu Rev Med; 2016 Dec 12; 67():309-21. PubMed ID: 26394285
    [Abstract] [Full Text] [Related]

  • 7. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N, MSBase Study Group.
    JAMA; 2019 Jan 15; 321(2):175-187. PubMed ID: 30644981
    [Abstract] [Full Text] [Related]

  • 8. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E, Joutseno J, Sumelahti ML.
    Clin Ther; 2017 Mar 15; 39(3):537-557.e10. PubMed ID: 28209373
    [Abstract] [Full Text] [Related]

  • 9. New management algorithms in multiple sclerosis.
    Sorensen PS.
    Curr Opin Neurol; 2014 Jun 15; 27(3):246-59. PubMed ID: 24759080
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui MK, Taneja A, Deniz B.
    Curr Med Res Opin; 2014 Apr 15; 30(4):613-27. PubMed ID: 24195574
    [Abstract] [Full Text] [Related]

  • 11. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F, Nourbakhsh B, Azimi AR.
    Mult Scler Relat Disord; 2020 Aug 15; 43():102195. PubMed ID: 32460086
    [Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S, Grimm S, van Hövell P, Freudensprung U, Pellegrini F, Hyde R, Bergmann A, NTD Study Group.
    J Neurol; 2018 Dec 15; 265(12):2980-2992. PubMed ID: 30327931
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity.
    Varytė G, Zakarevičienė J, Ramašauskaitė D, Laužikienė D, Arlauskienė A.
    Medicina (Kaunas); 2020 Jan 21; 56(2):. PubMed ID: 31973138
    [Abstract] [Full Text] [Related]

  • 18. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
    Gil-Bernal R, González-Caballero JL, Espinosa-Rosso R, Gómez-Gómez C.
    Sci Rep; 2021 Jun 15; 11(1):12533. PubMed ID: 34131191
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH, Wakefield RA.
    Am J Health Syst Pharm; 2015 Jan 01; 72(1):25-38. PubMed ID: 25511835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.